Zimmer Biomet (NYSE:ZBH) Upgraded at Barclays

Barclays upgraded shares of Zimmer Biomet (NYSE:ZBH) to a hold rating in a research report sent to investors on Wednesday,Zacks reports.

Several other research analysts also recently issued reports on the company. Sanford C. Bernstein lifted their price target on Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a research note on Thursday, August 6th. Wall Street Zen downgraded shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Wednesday, August 5th. Zacks Research raised shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 25th. Finally, UBS Group reiterated a “buy” rating and issued a $120.00 price target on shares of Zimmer Biomet in a research report on Thursday, August 6th. Six analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $103.33.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $89.05 on Wednesday. The firm has a market capitalization of $16.98 billion, a price-to-earnings ratio of 21.67, a price-to-earnings-growth ratio of 1.68 and a beta of 0.49. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. The business’s 50 day simple moving average is $95.70 and its 200-day simple moving average is $91.11. Zimmer Biomet has a 12 month low of $79.12 and a 12 month high of $106.88.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.06. The firm had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. Zimmer Biomet’s revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the firm posted $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, equities analysts forecast that Zimmer Biomet will post 8.54 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.36%.

Insider Activity

In other Zimmer Biomet news, insider Kevin R. Thornal sold 5,691 shares of the company’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $92.95, for a total value of $528,978.45. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Chad Phipps sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the sale, the insider directly owned 65,231 shares in the company, valued at $6,415,468.85. This represents a 4.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 1.28% of the company’s stock.

Institutional Trading of Zimmer Biomet

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Tacita Capital Inc acquired a new stake in Zimmer Biomet during the second quarter worth about $26,000. Monetary Solutions Ltd acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at about $30,000. Ancora Advisors LLC purchased a new stake in shares of Zimmer Biomet during the 2nd quarter worth about $29,000. Elevation Wealth Partners LLC grew its holdings in shares of Zimmer Biomet by 145.9% during the 2nd quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 229 shares during the period. Finally, Cornerstone Financial Management LLC acquired a new stake in Zimmer Biomet during the 4th quarter worth approximately $37,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. The company develops, manufactures and markets products used in orthopedic surgery, including total and partial knee, hip and shoulder replacement systems, sports medicine products, extremities, trauma devices and related surgical technologies.

Its portfolio also includes orthopedic surgical equipment, robotic- and computer-assisted technologies, biologics and other solutions designed to support joint reconstruction, spine procedures and dental applications.